论文部分内容阅读
目的研究联合吸入噻托溴铵及舒利迭对重度COPD肺功能和生活质量的影响。方法将2011年1月-2013年9月期间我院收治的重度慢性阻塞性肺疾病患者纳入研究,根据治疗方法不同分为给予噻托溴铵联合舒利迭吸入治疗的观察组和仅给予舒利迭吸入治疗的对照组,比较两组患者的肺功能和生活质量。结果观察组FVC(3.03±0.17)L、FEV1(3.25±0.28)L、FEV1/FVC(61.23±7.65)、FEV1%pred(67.69±5.08)、6MWD(408.44±54.47)m、自我实现、健康责任、运动、营养、人际关系、应对压力评分等生活质量评分(32.52±4.85、26.67±3.77、30.14±3.95、29.78±3.85、31.48±4.05、36.25±4.89)均明显高于对照组;MMRC(1.84±0.22)、步行后心率(81.94±9.33)次/min、呼吸频率(24.32±3.15)均明显低于对照组(P<0.05、0.01)。结论联合吸入噻托溴铵及舒利迭有助于改善肺功能、提高生活质量,是重度COPD患者理想的治疗方法。
Objective To investigate the effects of inhaled tiotropium and seretide on pulmonary function and quality of life in patients with severe COPD. Methods From January 2011 to September 2013 in our hospital admitted to patients with severe chronic obstructive pulmonary disease included in the study, according to the different treatment methods were divided into tiotropium combined with seretide inhalation therapy observation group and only given Shu In the control group, inhaled Losaladi, lung function and quality of life were compared between the two groups. Results FVC (3.03 ± 0.17) L, FEV1 (3.25 ± 0.28) L, FEV1 / FVC (61.23 ± 7.65), FEV1% pred (67.69 ± 5.08), 6MWD (408.44 ± 54.47) (32.52 ± 4.85,26.67 ± 3.77,30.14 ± 3.95,29.78 ± 3.85,31.48 ± 4.05,36.25 ± 4.89) were significantly higher than those in the control group. The scores of MMRC (1.84), physical activity, nutrition, interpersonal relationship, coping pressure and other quality of life scores ± 0.22), heart rate after walking (81.94 ± 9.33) times / min and respiratory rate (24.32 ± 3.15) were significantly lower than those in control group (P <0.05,0.01). Conclusions Combined inhalation of tiotropium and seretide can improve pulmonary function and improve quality of life and is an ideal treatment for patients with severe COPD.